Metabolomics and IDH1: Potential Therapeutic Targets to Block Glioma in Progression

Metabolomics and IDH1: Potential Therapeutic Targets to Block Glioma in Progression

Director of the renowned Abramson Cancer Center, Chi Van Dang, MD, PhD, reviews the role of isocitrate dehydrogenase 1 (IDH1) mutations in the aberrant metabolism of cancers, and their contribution to the gliomas. Beginning with the metabolism of cell growth and proliferation, Dr. Dang analyzes the metabolic impact of cancer-­associated IDH1 mutations in the gliomas and the effect of metabolic gene mutations on the metabolism of alpha­-ketoglutarate and its dependent enzymes. Finally, Dr Dang discusses current efforts to target and block the activity of ADH1 to halt the progression of the gliomas.

 

 

Related Links


Published

December 23, 2015

Created by

Penn Physician VideoLink